Study shows reliability and robustness of injectable anti-obesity medication – News-Medical.Net

A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier this month, establishing the reliability and robustness of this new drug. With obesity affecting more than 40 percent of American adults, the findings could have a major impact on weight management in primary care and other settings. The study is published today in the Journal of the American Medical Association.
The 68-week study was conducted at 41 sites in the…

Click here to view the original article.